#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: An individual participant data meta-analysis of 18 HIV prevention studies


In a meta-analysis of observational studies and randomized trials, Elizabeth A. Torrone and colleagues provide estimates of STI and BV prevalence among populations of sub-Saharan African women.


Vyšlo v časopise: Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: An individual participant data meta-analysis of 18 HIV prevention studies. PLoS Med 15(2): e32767. doi:10.1371/journal.pmed.1002511
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002511

Souhrn

In a meta-analysis of observational studies and randomized trials, Elizabeth A. Torrone and colleagues provide estimates of STI and BV prevalence among populations of sub-Saharan African women.


Zdroje

1. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS ONE. 2015;10(12):e0143304. doi: 10.1371/journal.pone.0143304 26646541

2. Looker KJ, Magaret AS, Turner KM, Vickerman P, Gottlieb SL, Newman LM. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS ONE. 2015;10(1):e114989. doi: 10.1371/journal.pone.0114989 25608026

3. Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. Am J Obstet Gynecol. 2013;209(6):505–23. doi: 10.1016/j.ajog.2013.05.006 23659989

4. World Health Organization. Global health sector strategy on sexually transmitted infections 2016–2021: towards ending STIs. Geneva: World Health Organization; 2016 Jul [cited 2017 Aug 3]. Available from: http://apps.who.int/iris/bitstream/10665/246296/1/WHO-RHR-16.09-eng.pdf?ua=1.

5. World Health Organization. Meeting report: consultation on methods for improved global sexually transmitted infections estimates. November 11–12, 2013, Geneva, Switzerland. Geneva: World Health Organization; 2014 Mar.

6. Morrison CS, Chen PL, Kwok C, Baeten JM, Brown J, Crook AM, et al. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. PLoS Med. 2015;12(1):e1001778. doi: 10.1371/journal.pmed.1001778 25612136

7. Baeten JM, Benki S, Chohan V, Lavreys L, McClelland RS, Mandaliya K, et al. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS. 2007;21(13):1771–7. doi: 10.1097/QAD.0b013e328270388a 17690576

8. Martin HL Jr, Nyange PM, Richardson BA, Lavreys L, Mandaliya K, Jackson DJ, et al. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis. 1998;178(4):1053–9. 9806034

9. Myer L, Denny L, Wright TC, Kuhn L. Prospective study of hormonal contraception and women’s risk of HIV infection in South Africa. Int J Epidemiol. 2007;36(1):166–74. doi: 10.1093/ije/dyl251 17175547

10. Myer L, Denny L, de Souza M, Wright TC Jr, Kuhn L. Distinguishing the temporal association between women’s intravaginal practices and risk of human immunodeficiency virus infection: a prospective study of South African women. Am J Epidemiol. 2006;163(6):552–60. doi: 10.1093/aje/kwj071 16443804

11. Morrison CS, Chen PL, Kwok C, Richardson BA, Chipato T, Mugerwa R, et al. Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS. 2010;24(11):1778–81. doi: 10.1097/QAD.0b013e32833a2537 20588106

12. Morrison CS, Skoler-Karpoff S, Kwok C, Chen PL, van de Wijgert J, Gehret-Plagianos M, et al. Hormonal contraception and the risk of HIV acquisition. AIDS. 2007;21(1):85–95. doi: 10.1097/QAD.0b013e3280117c8b 17148972

13. Kaul R, Kimani J, Nagelkerke NJ, Fonck K, Ngugi EN, Keli F, et al. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA. 2004;291(21):2555–62. doi: 10.1001/jama.291.21.2555 15173146

14. Vallely A, Kasindi S, Hambleton IR, Knight L, Chirwa T, Balira R, et al. Microbicides development program, Tanzania-baseline characteristics of an occupational cohort and reattendance at 3 months. Sex Transm Dis. 2007;34(9):638–43. doi: 10.1097/OLQ.0b013e3180325120 17717482

15. Watson-Jones D, Baisley K, Weiss HA, Tanton C, Changalucha J, Everett D, et al. Risk factors for HIV incidence in women participating in an HSV suppressive treatment trial in Tanzania. AIDS. 2009;23(3):415–22. doi: 10.1097/QAD.0b013e32831ef523 19114859

16. Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Baisley K, Mugeye K, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med. 2008;358(15):1560–71. doi: 10.1056/NEJMoa0800260 18337596

17. McCoy SI, Zheng W, Montgomery ET, Blanchard K, van der Straten A, de Bruyn G, et al. Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan Africa. AIDS. 2013;27(6):1001–9. doi: 10.1097/QAD.0b013e32835da401 23698064

18. Padian NS, van der Straten A, Ramjee G, Chipato T, de Bruyn G, Blanchard K, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet. 2007;370(9583):251–61. doi: 10.1016/S0140-6736(07)60950-7 17631387

19. Kleinschmidt I, Rees H, Delany S, Smith D, Dinat N, Nkala B, et al. Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort. Contraception. 2007;75(6):461–7. doi: 10.1016/j.contraception.2007.02.002 17519153

20. Delany-Moretlwe S, Rees H. Tshireletso study for women’s health. Microbicide feasibility study. Protocol. Hillbrow (South Africa): University of Witwatersrand Reproductive Health Research Unit; 2010.

21. McGrath N, Chimbwete C, Bennish M, Cassol S, Sturm W, Nunn A, et al. A feasibility study in preparation for phase III microbicide trials in the Hlabisa sub-district, South Africa. Southampton: University of Southampton; 2014 [cited 2018 Jan 29]. Available from: https://cdn.southampton.ac.uk/assets/imported/transforms/content-block/UsefulDownloads_Download/461D68EEDFED4C43B06EE08C8DF75A22/nuala%20mcgrath%20protocol%205.0.pdf#_ga=2.114160135.1656362442.1517285454-818325345.1517285454.

22. Kumwenda N, Kemewenda J, Kafulafula G, Makanani B, Taulo F, Nkhoma C, et al. HIV-1 incidence among women of reproductive age in Malawi. Int J STD AIDS. 2008;19:339–41. doi: 10.1258/ijsa.2007.007165 18482966

23. Kumwenda N, Hoffman I, Chirenje M, Kelly C, Coletti A, Ristow A, et al. HIV incidence among women of reproductive age in Malawi and Zimbabwe. Sex Transm Dis. 2006;33(11):646–51. doi: 10.1097/01.olq.0000223283.27142.9f 16773032

24. Morrison CS, Skoler-Karpoff S, Kwok C, Chen PL, van de Wijgert J, Gehret-Plagianos M, et al. Hormonal contraception and the risk of HIV acquisition among women in South Africa. AIDS. 2012;26(4):497–504. doi: 10.1097/QAD.0b013e32834fa13d 22156973

25. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9654):1977–87. doi: 10.1016/S0140-6736(08)61842-5 19059048

26. Vandepitte J, Bukenya J, Weiss HA, Nakubulwa S, Francis SC, Hughes P, et al. HIV and other sexually transmitted infections in a cohort of women involved in high-risk sexual behavior in Kampala, Uganda. Sex Transm Dis. 2011;38(4):316–23. 23330152

27. Kapiga SH, Ewings FM, Ao T, Chilongani J, Mongi A, Baisley K, et al. The epidemiology of HIV and HSV-2 infections among women participating in microbicide and vaccine feasibility studies in Northern Tanzania. PLoS ONE. 2013;8(7):e68825. doi: 10.1371/journal.pone.0068825 23874780

28. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis. 2012;12(1):19–26. doi: 10.1016/S1473-3099(11)70247-X 21975269

29. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010;362(5):427–39. doi: 10.1056/NEJMoa0904849 20089951

30. Crook AM, Ford D, Gafos M, Hayes R, Kamali A, Kapiga S, et al. Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial. Hum Reprod. 2014;29(8):1810–7. doi: 10.1093/humrep/deu113 24838704

31. McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010;376(9749):1329–37. doi: 10.1016/S0140-6736(10)61086-0 20851460

32. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74. doi: 10.1126/science.1193748 20643915

33. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22. doi: 10.1056/NEJMoa1202614 22784040

34. Low N, Chersich MF, Schmidlin K, Egger M, Francis SC, van de Wijgert JH, et al. Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis. PLoS Med. 2011;8(2):e1000416. doi: 10.1371/journal.pmed.1000416 21358808

35. Samoff E, Koumans EH, Gibson JJ, Ross M, Markowitz LE. Pre-treatment syphilis titers: distribution and evaluation of their use to distinguish early from late latent syphilis and to prioritize contact investigations. Sex Transm Dis. 2009;36(12):789–93. doi: 10.1097/OLQ.0b013e3181b3566b 19773682

36. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. doi: 10.1136/bmj.327.7414.557 12958120

37. World Health Organization. Global incidence and prevalence of selected sexually transmitted infections—2008. Geneva: World Health Organization; 2012 [cited 2017 Sep 23]. Available from: http://www.who.int/reproductivehealth/publications/rtis/stisestimates/en/.

38. Wijesooriya NS, Rochat RW, Kamb ML, Turlapati P, Temmerman M, Broutet N, et al. Global burden of maternal and congenital syphilis in 2008 and 2012: a health systems modelling study. Lancet Glob Health. 2016;4(8):e525–33. doi: 10.1016/S2214-109X(16)30135-8 27443780

39. Rabe LK, Kelly CW, Hillier SL. A comparison of the diagnosis of bacterial vaginosis by Amsel’s Clinical Criteria and the Vaginal Gram Staining Nugent score in HPTN 035. Microbicides 2008 Conference; 2008 Feb 24–27; New Delhi, India.

40. Patil MJ, Nagamoti JM, Metgud SC. Diagnosis of trichomonas vaginalis from vaginal specimens by wet mount microscopy, In Pouch TV culture system, and PCR. J Glob Infect Dis. 2012;4(1):22–5. doi: 10.4103/0974-777X.93756 22529623

41. van Dyck E, Buve A, Weiss HA, Glynn JR, Brown DW, De Deken B, et al. Performance of commercially available enzyme immunoassays for detection of antibodies against herpes simplex virus type 2 in African populations. J Clin Microbiol. 2004;42(7):2961–5. doi: 10.1128/JCM.42.7.2961-2965.2004 15243045

42. Abdool Karim Q, Baxter C, Birx D. Prevention of HIV in adolescent girls and young women: key to an AIDS-free generation. J Acquir Immune Defic Syndr. 2017;75(Suppl 1):S17–26.

43. Moodley D, Moodley P, Sebitloane M, Soowamber D, McNaughton-Reyes HL, Groves AK, et al. High prevalence and incidence of asymptomatic sexually transmitted infections during pregnancy and postdelivery in KwaZulu Natal, South Africa. Sex Transm Dis. 2015;42(1):43–7. doi: 10.1097/OLQ.0000000000000219 25504300

44. Giuliano AR, Botha MH, Zeier M, Abrahamsen ME, Glashoff RH, van der Laan LE, et al. High HIV, HPV, and STI prevalence among young Western Cape, South African women: EVRI HIV prevention preparedness trial. J Acquir Immune Defic Syndr. 2015;68(2):227–35. doi: 10.1097/QAI.0000000000000425 25415290

45. Pettifor AE, Rees HV, Kleinschmidt I, Steffenson AE, MacPhail C, Hlongwa-Madikizela L, et al. Young people’s sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. AIDS. 2005;19(14):1525–34. 16135907

46. World Health Organization, UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction. The importance of sexual and reproductive health and rights to prevent HIV in adolescent girls and young women in eastern and southern Africa. Geneva: World Health Organization; 2017 [cited 2017 Aug 3]. Available from: http://www.who.int/reproductivehealth/publications/linkages/hiv-prevention-adolescent-girls-young-women/en/.

47. Hayes R, Watson-Jones D, Celum C, van de Wijgert J, Wasserheit J. Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning? AIDS. 2010;24(Suppl 4):S15–26.

48. Kyongo JK, Crucitti T, Menten J, Hardy L, Cools P, Michiels J, et al. Cross-sectional analysis of selected genital tract immunological markers and molecular vaginal microbiota in sub-Saharan African women, with relevance to HIV risk and prevention. Clin Vaccine Immunol. 2015;22(5):526–38. doi: 10.1128/CVI.00762-14 25761460

49. Marston M, Slaymaker E, Cremin I, Floyd S, McGrath N, Kasamba I, et al. Trends and patterns in marriage and time spent single and sexually active in sub Saharan Africa, a comparative analysis of six community based cohort studies. Sex Transm Infect. 2009;85(Suppl 1):i64–71.

50. Hosegood V, McGrath N, Moultrie T. Dispensing with marriage: marital and partnership trends in rural KwaZulu-Natal, South Africa 2000–2006. Demogr Res. 2009;20:279–312. doi: 10.4054/DemRes.2009.20.13 25729322

51. Torrone E, Papp J, Weinstock H, Centers for Disease Control and Prevention (CDC). Prevalence of Chlamydia trachomatis genital infection among persons aged 14–39 years—United States, 2007–2012. MMWR Morb Mortal Wkly Rep. 2014;63(38):834–8. 25254560

52. Sonnenberg P, Clifton S, Beddows S, Field N, Soldan K, Tanton C, et al. Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet. 2013;382(9907):1795–806. doi: 10.1016/S0140-6736(13)61947-9 24286785

53. World Health Organization. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Geneva: World Health Organization; 2012 [cited 2017 Aug 3]. Available from: http://www.who.int/reproductivehealth/publications/rtis/9789241503501/en/.

54. World Health Organization. Investment case for eliminating mother-to-child transmission of syphilis: promoting better maternal and child health and stronger health systems. Geneva: World Health Organization; 2012 [cited 2017 Aug 3]. Available from: http://www.who.int/reproductivehealth/publications/rtis/9789241504348/en/.

55. World Health Organization. Guidelines for the management of sexually transmitted infections. Geneva: World Health Organization; 2004 [cited 2017 Aug 3]. Available from: http://www.who.int/hiv/pub/sti/pub6/en/.

56. Garrett NJ, McGrath N, Mindel A. Advancing STI care in low/middle-income countries: has STI syndromic management reached its use-by date? Sex Transm Infect. 2017;93(1):4–5. doi: 10.1136/sextrans-2016-052581 27084840

57. Gottlieb SL, Low N, Newman LM, Bolan G, Kamb M, Broutet N. Toward global prevention of sexually transmitted infections (STIs): the need for STI vaccines. Vaccine. 2014;32(14):1527–35. doi: 10.1016/j.vaccine.2013.07.087 24581979

58. Broutet N, Fruth U, Deal C, Gottlieb SL, Rees H, participants of the 2013 STI Vaccine Technical Consultation. Vaccines against sexually transmitted infections: the way forward. Vaccine. 2014;32(14):1630–7. doi: 10.1016/j.vaccine.2014.01.053 24480024

59. Johnston C, Gottlieb SL, Wald A. Status of vaccine research and development of vaccines for herpes simplex virus. Vaccine. 2016;34(26):2948–52. doi: 10.1016/j.vaccine.2015.12.076 26973067

60. Looker KJ, Elmes JAR, Gottlieb SL, Schiffer JT, Vickerman P, Turner KME, et al. The effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. Lancet Infect Dis. 2017;17(12):1303–16. doi: 10.1016/S1473-3099(17)30405-X 28843576

61. Petousis-Harris H, Paynter J, Morgan J, Saxton P, McArdle B, Goodyear-Smith F, et al. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet. 2017;390(10102):1603–10. doi: 10.1016/S0140-6736(17)31449-6 28705462

62. Fox J, Fidler S. Sexual transmission of HIV-1. Antiviral Res. 2010 Jan;85(1):276–85. doi: 10.1016/j.antiviral.2009.10.012 19874852

63. Chico RM, Mayaud P, Ariti C, Mabey D, Ronsmans C, Chandramohan D. Prevalence of malaria and sexually transmitted and reproductive tract infections in pregnancy in sub-Saharan Africa: a systematic review. JAMA. 2012;307(19):2079–86. doi: 10.1001/jama.2012.3428 22665107

Štítky
Interné lekárstvo

Článok vyšiel v časopise

PLOS Medicine


2018 Číslo 2
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Aktuální možnosti diagnostiky a léčby litiáz
nový kurz
Autori: MUDr. Tomáš Ürge, PhD.

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#